{"anticipatedPostingDate":"2028-09","calculatePct":false,"denomUnitsSelected":"Participants","description":"TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose reductions with tucatinib, trastuzumab and pertuzumab are reported. Dose reduction requirements are defined per protocol.","reportingStatus":"NOT_POSTED","timeFrame":"From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)","title":"Number of Participants With TEAEs Leading to Dose Reductions","type":"SECONDARY"}